BIIB250103P220000
- 0.00
- 0.000.00%
Biogen Newsroom
Truist Financial Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $220
Truist Financial Sticks to Their Buy Rating for Biogen (BIIB)
Solid Biosciences Stock Jumps 11% Post-market on FDA Update
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
HealthTech Business Organisation Study: How to Organize Digital Health Businesses, Especially at Large Pharma and MedTech Companies - ResearchAndMarkets.com
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Cuts Target Price to $231
Biogen to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Healthcare Sector's 2024 Gainers and Losers: Intuitive Surgical, Boston Scientific Tops Chart
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Guggenheim Adjusts Price Target on Biogen to $190 From $245, Maintains Buy Rating
Biogen Shares Lower After Piper Sandler Downgrade
17 Analysts Assess Biogen: What You Need To Know
Biogen Price Target Cut to $138.00/Share From $315.00 by Piper Sandler
Biogen Analyst Ratings
Express News | Piper Sandler has downgraded Biogen's rating to neutral.
These Battered S&P 500 Stocks Could Be Ripe for a Turnaround in 2025
Express News | Biogen : Piper Sandler Cuts to Neutral From Overweight
Why Biogen Inc. (BIIB) Is a Top Value Stock for the Long-Term
The U.S. stock market officially closed for 2024! Among the components of the three major stock indices, who performed the best and who performed the worst?
AppLovin, a constituent stock of the Nasdaq, surged by 713%, becoming the biggest dark horse, with an increase more than four times that of AI leader NVIDIA.
These Are the Best and Worst Stocks This Year